Nootropic Peptides is a recurring topic in our peptide coverage. This hub collects every article tagged Nootropic Peptides, newest first, each evidence-graded and tied to real, verifiable sources.
A clinical, evidence-graded ranking of the peptides marketed for memory — Cerebrolysin, Semax, Noopept, Dihexa and P021 — separating the disputed human RCT signal from preclinical mechanism, a retracted-data scandal, and pure marketing.
A clinical, evidence-graded look at the peptides marketed for focus and "brain fog" — Semax, Selank, Cerebrolysin and the N-Acetyl modified analogs — separating the small human attention signal from preclinical mechanism and pure marketing.
A clinical monograph on Semax — the Russian-developed ACTH(4-10) heptapeptide used intranasally for stroke recovery and cognition. Real but single-country human data, graded B, with an unsettled 2026 FDA status.
A clinical monograph on Noopept (omberacetam) — the proline-glycine dipeptide nootropic and cycloprolylglycine prodrug. Small Russian human trials in cognitive impairment, a deep preclinical mechanism, and an unsettled 2026 legal status.
A clinical monograph on Selank (TP-7) — the Russian tuftsin-analog anxiolytic peptide. Small human anxiety trials, a mostly preclinical mechanism, and an unsettled 2026 US legal status.
A clinical monograph on P21 (P021, Ac-DGGLAG-NH2) — a small-molecule CNTF mimetic marketed as a nootropic peptide. Reproducible rodent neurogenesis and anti-tau data, but zero human trials and an unapproved-research-chemical status.
A clinical monograph on N-Acetyl Semax Amidate — the terminally-stabilized analog of the Russian nootropic Semax. No human or animal data on the modified molecule, an unproven potency story, and an unsettled 2026 legal status.
A clinical monograph on N-Acetyl Selank Amidate — a twice-stabilized analog of the Russian anxiolytic peptide Selank. No dedicated human or animal study exists; every claim is extrapolated, placing the analog itself at evidence grade D.
A clinical monograph on FGL (FGLL) — the NCAM-derived FGFR1 agonist peptide marketed for memory and neuroprotection. Deep rodent data, one single-dose human safety study, and zero efficacy proof in people.
A clinical monograph on Pinealon (Glu-Asp-Arg / EDR), the Khavinson ultrashort neuroprotective tripeptide. Reproducible preclinical antioxidant data, no human RCT, and an unapproved 2026 legal status.
A clinical monograph on dihexa — the angiotensin IV-derived nootropic peptide promoted for cognition. Its evidence is preclinical only, its foundational mechanism papers were retracted for fraud, and its clinical prodrug failed an Alzheimer's trial.
Nootropic Peptides is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Nootropic Peptides, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.